Chlorpromazine

Dosage for chlorpromazine is highly individualized and depends significantly on the condition being treated, the severity of symptoms, and the patient's overall health. Healthcare providers typically start with a low dose and gradually increase it (titration) to find the minimum effective dose.

• Psychotic Disorders (Outpatients): Initial doses may range from 10 mg to 25 mg three to four times daily. For more severe cases, doses may be increased to 200 mg per day. Some chronic patients may require 500 mg to 1,000 mg daily, though high doses increase the risk of side effects.
• Psychotic Disorders (Hospitalized/Acute): Initial doses may be higher, often 25 mg IM initially, followed by oral doses of 25 mg to 50 mg three times daily, increasing gradually as needed.
• Nausea and Vomiting: 10 mg to 25 mg every 4 to 6 hours as needed. If using IM, 25 mg is a common starting dose.
• Intractable Hiccups: 25 mg to 50 mg orally three or four times daily. If hiccups persist for 2-3 days, 25 mg to 50 mg may be given by IM injection.
• Pre-operative Apprehension: 25 mg to 50 mg orally 2 to 3 hours before surgery.

Chlorpromazine is approved for use in children aged 6 months and older, though it is most commonly used in children over 2 years of age for specific indications.

• Severe Behavioral Problems: The typical oral dose is 0.5 mg per kilogram of body weight every 4 to 6 hours. For a child weighing 20 kg, this would be approximately 10 mg per dose. The maximum daily dose for children under 5 years is generally 40 mg, and for children aged 5 to 12, it is 75 mg, unless the severity of the condition requires more.
• Nausea and Vomiting: The dosage is similar to that for behavioral problems (0.5 mg/kg), adjusted based on the child's response and the healthcare provider's recommendation.

Renal Impairment

While chlorpromazine is primarily metabolized by the liver, its metabolites are excreted by the kidneys. Patients with significant renal impairment should be monitored closely, and healthcare providers may consider lower starting doses to prevent the accumulation of metabolites.

Hepatic Impairment

Because the liver is the primary site of chlorpromazine metabolism, patients with liver disease (such as cirrhosis or hepatitis) are at a much higher risk of toxicity. Dosage should be initiated at the lowest possible level, and frequent monitoring of liver function tests is essential.

Elderly Patients

Geriatric patients are often more sensitive to the sedative and hypotensive effects of chlorpromazine. Healthcare providers typically use doses that are 1/2 to 1/3 of the standard adult dose. There is also an increased risk of tardive dyskinesia and other movement disorders in this population.

• Consistency: Take the medication at the same time(s) each day to maintain stable blood levels.
• With or Without Food: Chlorpromazine can be taken with or without food. Taking it with food or a glass of milk may help reduce stomach upset.
• Oral Liquid: Use a calibrated measuring device (not a household spoon) to ensure the correct dose of oral concentrate. Dilute the concentrate in juice, water, or soft food as directed by the pharmacist.
• Storage: Store tablets and liquid at room temperature, away from moisture, heat, and direct light. Do not allow the liquid formulation to freeze.
• Avoid Skin Contact: The liquid concentrate can cause contact dermatitis (skin rash). Avoid getting the liquid on your skin or clothing.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of severe side effects.

Signs of a chlorpromazine overdose may include extreme drowsiness, irregular heartbeat, fainting, muscle stiffness, tremors, and agitation. In severe cases, an overdose can lead to coma or seizures. If an overdose is suspected, contact emergency medical services or a poison control center immediately. Emergency treatment often involves gastric lavage (stomach pumping) and supportive care to maintain breathing and heart function.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can cause withdrawal symptoms.

Chlorpromazine is associated with several common side effects that often occur during the initial weeks of treatment as the body adjusts to the medication. These include:

• Drowsiness and Sedation: This is the most frequently reported side effect. It is often most intense during the first few days of therapy and may subside over time. Patients should avoid driving until they know how the drug affects them.
• Dry Mouth (Xerostomia): Due to its anticholinergic properties, chlorpromazine reduces saliva production. This can be managed by sipping water or using sugarless gum.
• Blurred Vision: Difficulty focusing on near objects is common and usually temporary.
• Constipation: Reduced gastrointestinal motility is a known effect; increasing fiber and fluid intake may help.
• Weight Gain: Many patients experience an increase in appetite and metabolic changes that lead to weight gain over time.

• Orthostatic Hypotension: A sudden drop in blood pressure when standing up, which can cause dizziness or fainting.
• Urinary Retention: Difficulty starting urination or fully emptying the bladder.
• Photosensitivity: Increased sensitivity to sunlight, making the skin more prone to severe sunburn.
• Nasal Congestion: A 'stuffy nose' feeling due to the drug's effect on blood vessels in the nasal passages.
• Amenorrhea or Galactorrhea: Changes in menstrual cycles or unexpected breast milk production due to increased prolactin levels.

• Agranulocytosis: A dangerous drop in white blood cell counts that makes the body highly susceptible to infection.
• Cholestatic Jaundice: A liver condition characterized by yellowing of the skin and eyes, usually occurring within the first month of treatment.
• Ocular Changes: Long-term use of high doses can lead to deposits in the lens and cornea of the eye.
• Priapism: A painful, prolonged erection that requires emergency medical intervention.

> Warning: Stop taking Chlorpromazine and call your doctor immediately if you experience any of these serious conditions.

• Neuroleptic Malignant Syndrome (NMS): A life-threatening reaction characterized by high fever, stiff muscles, confusion, sweating, and irregular heart rate. This is a medical emergency.
• Extrapyramidal Symptoms (EPS): These are movement disorders that include:
• Akathisia: An intense feeling of restlessness and an inability to sit still.
• Dystonia: Involuntary muscle contractions, often in the neck, jaw, or tongue.
• Pseudoparkinsonism: Symptoms resembling Parkinson's disease, such as tremors, shuffling gait, and muscle stiffness.
• Tardive Dyskinesia (TD): A potentially irreversible condition involving repetitive, involuntary movements, most commonly of the face, tongue, and mouth (e.g., lip-smacking, tongue thrusting). The risk increases with the duration of treatment and total cumulative dose.
• QT Prolongation: An alteration in the heart's electrical activity that can lead to dangerous heart rhythms (arrhythmias).

Prolonged use of chlorpromazine can lead to chronic metabolic issues, including an increased risk of developing Type 2 diabetes and high cholesterol. Additionally, the risk of Tardive Dyskinesia increases the longer a patient remains on the medication. Regular 'skin and eye' exams are recommended for those on high-dose, long-term therapy to monitor for pigmentary changes in the skin or lens opacities.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: The FDA has issued a black box warning stating that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Most deaths appeared to be cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Chlorpromazine is NOT approved for the treatment of patients with dementia-related psychosis.

Report any unusual symptoms or changes in mood/behavior to your healthcare provider immediately.

Chlorpromazine is a potent medication that requires careful medical supervision. It can significantly impair mental and physical abilities, especially during the initiation of therapy. Patients must be aware that the full therapeutic effect for psychiatric conditions may take several weeks to manifest, and they should not discontinue the drug abruptly without consulting their healthcare provider.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Clinical trials have shown that elderly patients with dementia-related psychosis who are treated with antipsychotic medications, including phenothiazines like chlorpromazine, face a significantly higher risk of death compared to those receiving a placebo. Chlorpromazine is not indicated for the treatment of psychosis associated with dementia, and healthcare providers should consider alternative treatments for this population.

• Allergic Reactions: Though rare, severe allergic reactions (anaphylaxis) can occur. Patients with a known hypersensitivity to other phenothiazines (e.g., prochlorperazine, promethazine) may experience cross-sensitivity and should use chlorpromazine with extreme caution.
• Hepatotoxicity: Chlorpromazine has been linked to liver injury, specifically cholestatic jaundice. If a patient develops yellowing of the eyes/skin, dark urine, or upper abdominal pain, the drug should be discontinued immediately.
• Seizure Threshold: Chlorpromazine can lower the seizure threshold. Patients with a history of epilepsy or those undergoing withdrawal from alcohol or sedatives should be monitored closely for increased seizure activity.
• Bone Marrow Suppression: Rare but fatal cases of agranulocytosis (severe low white blood cell count) have been reported. Patients should report any signs of infection, such as fever or sore throat, immediately for blood count testing.
• QT Prolongation: This medication can affect the heart's rhythm. It should be used with caution in patients with pre-existing heart disease, low potassium or magnesium levels, or those taking other medications that prolong the QT interval.

To ensure safety while taking chlorpromazine, healthcare providers will typically order regular diagnostic tests:

• Complete Blood Count (CBC): To monitor for white blood cell changes, especially during the first few months.
• Liver Function Tests (LFTs): To check for signs of drug-induced liver irritation.
• A1C and Lipid Panel: To monitor for metabolic changes, such as increased blood sugar or cholesterol.
• Eye Exams: For patients on long-term therapy to check for retinal or corneal deposits.
• AIMS Examination: The Abnormal Involuntary Movement Scale (AIMS) is used to screen for signs of tardive dyskinesia.

Chlorpromazine causes significant drowsiness and can slow reaction times. Patients should not drive, operate heavy machinery, or engage in potentially dangerous activities until they are certain that the medication does not impair their ability to do so safely.

Alcohol must be strictly avoided while taking chlorpromazine. Alcohol significantly enhances the CNS depressant effects of the medication, leading to extreme sedation, respiratory depression, and an increased risk of accidental injury or overdose.

Stopping chlorpromazine suddenly can lead to 'withdrawal emergent' symptoms, including nausea, vomiting, dizziness, and tremors. It may also cause a rapid return of psychotic symptoms. Healthcare providers will always recommend a gradual tapering of the dose over several weeks or months to ensure a safe transition.

> Important: Discuss all your medical conditions, including any history of heart, liver, or kidney disease, with your healthcare provider before starting Chlorpromazine.

Certain medications should never be used in combination with chlorpromazine due to the risk of life-threatening complications:

• Cisapride: Combining these can lead to fatal cardiac arrhythmias due to additive QT prolongation effects.
• Grepanfloxacin or Sparfloxacin: These antibiotics significantly increase the risk of Torsades de Pointes (a dangerous heart rhythm) when taken with phenothiazines.
• Strong CYP2D6 Inhibitors: Medications that completely block the enzyme responsible for breaking down chlorpromazine can lead to toxic drug levels.

• CNS Depressants: Medications such as benzodiazepines (e.g., diazepam, lorazepam), opioids (e.g., oxycodone, morphine), and barbiturates have additive effects with chlorpromazine. This can lead to profound sedation, respiratory distress, and coma.
• Anticholinergic Drugs: Drugs like benztropine, atropine, or certain antihistamines can worsen the 'drying' side effects of chlorpromazine, leading to severe constipation, heatstroke (due to inability to sweat), or paralytic ileus (bowel obstruction).
• Antihypertensives: Chlorpromazine can enhance the effects of blood pressure medications, particularly alpha-blockers, potentially causing severe hypotension (dangerously low blood pressure).
• Epinephrine: Chlorpromazine can reverse the vasopressor effect of epinephrine. If a patient on chlorpromazine requires treatment for a severe allergic reaction, epinephrine may actually lower the blood pressure further (a phenomenon known as 'epinephrine reversal').

• Lithium: When used together, there is a risk of neurotoxicity or an encephalopathic syndrome, characterized by weakness, fever, and tremors. Patients on both should be monitored for neurological changes.
• Anticonvulsants: Chlorpromazine may lower the seizure threshold, requiring an adjustment in the dose of anti-seizure medications like phenytoin or valproic acid.
• Levodopa: Chlorpromazine blocks dopamine receptors, which directly opposes the action of levodopa used in Parkinson's disease, rendering the Parkinson's treatment less effective.

• Caffeine: High intake of caffeine may reduce the sedative effects of chlorpromazine and, in some cases, may interfere with the drug's absorption or metabolism.
• Alcohol: As noted previously, alcohol is a major interaction that increases the risk of severe CNS depression and should be avoided entirely.

• St. John's Wort: This herb can induce liver enzymes, potentially lowering the concentration of chlorpromazine in the blood and reducing its effectiveness.
• Kava Kava and Valerian Root: These supplements have sedative properties that can dangerously increase the drowsiness caused by chlorpromazine.
• Evening Primrose Oil: Some evidence suggests this supplement may lower the seizure threshold, increasing the risk of seizures when combined with phenothiazines.

Chlorpromazine can interfere with certain medical tests, leading to false results:

• Pregnancy Tests: May cause false-positive results in urine pregnancy tests.
• Urine Bilirubin: May produce false-positive results for bilirubin in the urine.
• Phenylketonuria (PKU) Tests: May interfere with the results of tests for PKU.

For each major interaction, the management strategy usually involves either avoiding the combination, adjusting the dosage, or performing frequent clinical monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter cold or allergy medicines.

Chlorpromazine must NEVER be used in the following circumstances:

• Known Hypersensitivity: Patients who have had a severe allergic reaction to chlorpromazine or any other phenothiazine (such as fluphenazine or perphenazine) should not take this drug. The mechanism is an immune-mediated response that can lead to anaphylaxis.
• Comatose States: Chlorpromazine should not be administered to patients in a coma, as it can further depress the central nervous system and mask the underlying cause of the coma.
• Severe CNS Depression: Patients who are already experiencing significant central nervous system depression (for example, from a massive overdose of alcohol, barbiturates, or narcotics) should not receive chlorpromazine.
• Bone Marrow Depression: Because chlorpromazine can cause blood dyscrasias, it is contraindicated in patients who already have significant bone marrow suppression or a history of drug-induced agranulocytosis.

In these situations, the healthcare provider must carefully weigh the benefits against the potential risks:

• Cardiovascular Disease: Due to the risk of hypotension and QT prolongation, patients with heart failure, recent heart attack, or arrhythmias require extreme caution.
• Respiratory Disease: Patients with severe asthma, emphysema, or acute respiratory infections may be at risk because chlorpromazine can suppress the cough reflex and cause respiratory depression.
• Glaucoma: The anticholinergic effects of chlorpromazine can increase intraocular pressure, potentially worsening narrow-angle glaucoma.
• Prostatic Hypertrophy: Men with an enlarged prostate may experience severe urinary retention due to the drug's anticholinergic properties.
• Pheochromocytoma: This rare tumor of the adrenal gland can cause blood pressure instability, which chlorpromazine may exacerbate.

There is a high degree of cross-sensitivity among the phenothiazine class. If a patient has experienced cholestatic jaundice, skin rashes, or blood disorders while taking another phenothiazine medication, they are at a significantly increased risk of experiencing the same reaction with chlorpromazine. Patients should always inform their healthcare provider of any past adverse reactions to psychiatric or anti-nausea medications.

> Important: Your healthcare provider will evaluate your complete medical history, including any underlying physical conditions, before prescribing Chlorpromazine.

Chlorpromazine is classified by the FDA as Pregnancy Category C. This means that animal studies have shown adverse effects on the fetus, but there are no adequate and well-controlled studies in humans.

• Third Trimester Risks: Neonates exposed to antipsychotic drugs like chlorpromazine during the third trimester are at risk for extrapyramidal symptoms (EPS) and withdrawal symptoms after birth. These symptoms can include agitation, hypertonia (muscle stiffness), hypotonia (floppiness), tremor, and respiratory distress.
• Clinical Consideration: Chlorpromazine should only be used during pregnancy if the potential benefit to the mother outweighs the potential risk to the fetus. If treatment is necessary, the lowest effective dose should be used.

Chlorpromazine is excreted into human breast milk. Because of the potential for serious adverse reactions in nursing infants (such as extreme lethargy or developmental delays), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Most clinical guidelines suggest that if a mother must take chlorpromazine, the infant should be closely monitored for sedation and developmental milestones.

While chlorpromazine is used in children for severe behavioral problems and nausea, it is not generally recommended for children under 6 months of age. In older children, it should be used with caution as they may be more susceptible to neuromuscular reactions (dystonias). There is also concern that the drug's sedative effects could interfere with learning and school performance. Long-term effects on growth and development in children have not been extensively studied.

As noted in the Black Box Warning, elderly patients with dementia are at an increased risk of death. Even in elderly patients without dementia, chlorpromazine is associated with a high risk of falls due to sedation and orthostatic hypotension. The 'Beers Criteria' for potentially inappropriate medication use in older adults lists chlorpromazine as a drug to avoid or use with extreme caution. Age-related declines in liver and kidney function also mean that the drug stays in the system longer, increasing the risk of toxicity.

In patients with kidney disease, the excretion of chlorpromazine metabolites is delayed. While the parent drug is metabolized by the liver, the accumulation of metabolites can lead to increased side effects. Healthcare providers typically use a 'start low, go slow' approach for patients with a GFR (Glomerular Filtration Rate) below 60 mL/min.

Chlorpromazine is contraindicated or used with extreme caution in patients with active liver disease. In patients with chronic hepatic impairment (Child-Pugh Class B or C), the drug's half-life is significantly prolonged, and the risk of drug-induced coma or encephalopathy is elevated. Frequent monitoring of liver enzymes is mandatory in this population.

> Important: Special populations require individualized medical assessment and frequent follow-up with a healthcare provider to ensure safety and efficacy.

Chlorpromazine is a multi-receptor antagonist. Its primary antipsychotic effect is derived from its high affinity for Dopamine D2 receptors in the limbic system and basal ganglia. By blocking these receptors, it reduces excessive dopaminergic activity, which is hypothesized to be the cause of 'positive' psychotic symptoms.

Beyond dopamine, it acts as an antagonist at:

• Alpha-1 Adrenergic Receptors: Leading to vasodilation and sedation.
• H1 Histamine Receptors: Contributing to its potent sedative and anti-pruritic (anti-itch) properties.
• M1 and M2 Muscarinic Receptors: Causing classic anticholinergic effects.
• 5-HT2 Serotonin Receptors: Which may modulate its effects on mood and movement.

Its antiemetic effect is achieved by blocking dopamine receptors in the Chemoreceptor Trigger Zone (CTZ) of the medulla, the area of the brain that triggers the vomiting reflex.

• Onset of Action: For psychiatric symptoms, the sedative effect may be seen within hours, but the true antipsychotic effect typically takes 2 to 4 weeks of consistent dosing. For nausea or hiccups, the effect is much faster, often within 30 to 60 minutes of an oral dose.
• Duration: The effects of a single oral dose typically last for 4 to 6 hours, though the half-life suggests that the drug remains in the system much longer.
• Tolerance: While patients do not typically develop tolerance to the antipsychotic effects, they often develop tolerance to the sedative and hypotensive effects within the first few weeks of treatment.

| Parameter | Value |

|---|---|

| Bioavailability | 25% - 35% (Extensive first-pass metabolism) |

| Protein Binding | 92% - 97% (Primarily Albumin) |

| Half-life | 24 - 31 hours (Highly variable) |

| Tmax (Oral) | 1.5 - 4 hours |

| Metabolism | Hepatic (CYP2D6, CYP1A2, CYP3A4) |

| Excretion | Renal (Metabolites) and Biliary/Fecal |

• Molecular Formula: C17H19ClN2S
• Molecular Weight: 318.86 g/mol
• Solubility: Highly soluble in water and ethanol; lipophilic nature allows for high tissue distribution.
• Structure: It is a propylamino derivative of phenothiazine, characterized by a three-ring structure with a chlorine atom at the 2-position and a dimethylaminopropyl side chain at the 10-position.

Chlorpromazine is the prototype of the Phenothiazine class of typical antipsychotics. It is specifically categorized as a 'low-potency' agent, meaning it requires higher milligram doses to achieve the same D2 blockade as 'high-potency' agents like haloperidol, but it carries a higher risk of sedation and anticholinergic effects and a slightly lower (though still significant) risk of acute extrapyramidal symptoms.